{"name":"Otsuka Pharmaceutical Co., Ltd.","slug":"otsuka-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"otsuka.com","description":"Otsuka Pharmaceutical Co., Ltd. , abbreviated OPC, is a pharmaceutical company headquartered in Chiyoda, Tokyo. The company was established on August 10, 1964.","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":21,"colorKey":"oncology","drugs":[{"name":"Physulime","genericName":"MOZAVAPTAN","slug":"mozavaptan","indication":"Paraneoplastic hyponatremia","status":"marketed"},{"name":"OPC-249","genericName":"OPC-249","slug":"opc-249","indication":"Other","status":"phase_2"},{"name":"Tolvaptan tablet 15mg","genericName":"Tolvaptan tablet 15mg","slug":"tolvaptan-tablet-15mg","indication":"Other","status":"phase_1"},{"name":"14C-OPS-2071","genericName":"14C-OPS-2071","slug":"14c-ops-2071","indication":"Other","status":"phase_1"},{"name":"OPC-18","genericName":"OPC-18","slug":"opc-18","indication":"Other","status":"phase_2"},{"name":"Samtasu for I.V. infusion","genericName":"Samtasu for I.V. infusion","slug":"samtasu-for-i-v-infusion","indication":"Other","status":"phase_2"},{"name":"99mTc sulfur colloid","genericName":"99mTc sulfur colloid","slug":"99mtc-sulfur-colloid","indication":"Other","status":"phase_2"},{"name":"ASC-01","genericName":"ASC-01","slug":"asc-01","indication":"Muscle wasting and weakness in older adults","status":"phase_3"},{"name":"ASTX660","genericName":"ASTX660","slug":"astx660","indication":"Other","status":"phase_1"},{"name":"Aripiprazole oral product","genericName":"Aripiprazole oral product","slug":"aripiprazole-oral-product","indication":"Other","status":"phase_3"},{"name":"OCV-501","genericName":"OCV-501","slug":"ocv-501","indication":"Other","status":"phase_2"},{"name":"OPB-31121 phase2","genericName":"OPB-31121 phase2","slug":"opb-31121-phase2","indication":"Other","status":"phase_1"},{"name":"OPC-14597 IMD","genericName":"OPC-14597 IMD","slug":"opc-14597-imd","indication":"Other","status":"phase_1"},{"name":"OPC-41061 （Tolvaptan)","genericName":"OPC-41061 （Tolvaptan)","slug":"opc-41061-tolvaptan","indication":"Hyponatremia in hospitalized patients","status":"phase_3"},{"name":"OPC-415","genericName":"OPC-415","slug":"opc-415","indication":"Other","status":"phase_1"},{"name":"OPC-61815 injection","genericName":"OPC-61815 injection","slug":"opc-61815-injection","indication":"Chemotherapy-induced nausea and vomiting (CINV)","status":"phase_3"},{"name":"Placebo of Aripiprazole","genericName":"Placebo of Aripiprazole","slug":"placebo-of-aripiprazole","indication":"Control arm in phase 3 clinical trials of aripiprazole","status":"phase_3"},{"name":"Placebo of CDP870","genericName":"Placebo of CDP870","slug":"placebo-of-cdp870","indication":"Other","status":"phase_3"},{"name":"Placebo of SPM 962","genericName":"Placebo of SPM 962","slug":"placebo-of-spm-962","indication":"Other","status":"phase_3"},{"name":"Placebo of tolvaptan","genericName":"Placebo of tolvaptan","slug":"placebo-of-tolvaptan","indication":"Other","status":"marketed"},{"name":"SGI-110","genericName":"SGI-110","slug":"sgi-110","indication":"Other","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"respiratory","drugs":[{"name":"Aripiprazole (Fixed dose)","genericName":"Aripiprazole (Fixed dose)","slug":"aripiprazole-fixed-dose","indication":"Schizophrenia","status":"phase_3"},{"name":"Aripiprazole (Titrated dose)","genericName":"Aripiprazole (Titrated dose)","slug":"aripiprazole-titrated-dose","indication":"Schizophrenia","status":"phase_3"},{"name":"OPC-12759","genericName":"OPC-12759","slug":"opc-12759","indication":"Treatment of schizophrenia","status":"phase_3"},{"name":"OPC-14597 (Aripiprazole)","genericName":"OPC-14597 (Aripiprazole)","slug":"opc-14597-aripiprazole","indication":"Schizophrenia","status":"phase_3"},{"name":"OPC-34712FUM/ Brexpiprazole fumarate","genericName":"OPC-34712FUM/ Brexpiprazole fumarate","slug":"opc-34712fum-brexpiprazole-fumarate","indication":"Schizophrenia","status":"phase_3"},{"name":"OPC-6535","genericName":"OPC-6535","slug":"opc-6535","indication":"Neuropathic pain","status":"phase_3"},{"name":"SPM 962","genericName":"SPM 962","slug":"spm-962","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"neuroscience","drugs":[{"name":"TEV-48125","genericName":"TEV-48125","slug":"tev-48125","indication":"Atrial fibrillation for stroke prevention","status":"phase_3"},{"name":"Carteolol long-acting ophthalmic solution","genericName":"Carteolol long-acting ophthalmic solution","slug":"carteolol-long-acting-ophthalmic-solution","indication":"Glaucoma","status":"phase_3"},{"name":"OPC-41061","genericName":"OPC-41061","slug":"opc-41061","indication":"Hyponatremia associated with heart failure","status":"phase_3"},{"name":"Tolvaptan Oral Tablet","genericName":"Tolvaptan Oral Tablet","slug":"tolvaptan-oral-tablet","indication":"Hyponatremia associated with syndrome of inappropriate antidiuretic hormone secretion (SIADH)","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"rare","drugs":[{"name":"Hyalein Mini Ophthalmic solution","genericName":"Hyalein Mini Ophthalmic solution","slug":"hyalein-mini-ophthalmic-solution","indication":"Dry eye disease","status":"phase_3"},{"name":"OPC-1085EL ophthalmic solution","genericName":"OPC-1085EL ophthalmic solution","slug":"opc-1085el-ophthalmic-solution","indication":"Treatment of dry eye disease","status":"phase_3"},{"name":"OPC-12759 Ophthalmic suspension","genericName":"OPC-12759 Ophthalmic suspension","slug":"opc-12759-ophthalmic-suspension","indication":"Treatment of dry eye syndrome","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CDP870","genericName":"CDP870","slug":"cdp870","indication":"Rheumatoid arthritis","status":"phase_3"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Moizerto","genericName":"DIFAMILAST","slug":"difamilast","indication":"Atopic dermatitis","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"13C-uracil","genericName":"13C-uracil","slug":"13c-uracil","indication":"Assessment of pyrimidine metabolism in cancer","status":"phase_2"}]}],"pipeline":[{"name":"Physulime","genericName":"MOZAVAPTAN","slug":"mozavaptan","phase":"marketed","mechanism":"Vasopressin V2 receptor","indications":["Paraneoplastic hyponatremia"],"catalyst":""},{"name":"OPC-249","genericName":"OPC-249","slug":"opc-249","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tolvaptan tablet 15mg","genericName":"Tolvaptan tablet 15mg","slug":"tolvaptan-tablet-15mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"14C-OPS-2071","genericName":"14C-OPS-2071","slug":"14c-ops-2071","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CDP870","genericName":"CDP870","slug":"cdp870","phase":"phase_3","mechanism":"CDP870 is a pegylated TNF-alpha inhibitor that binds and neutralizes tumor necrosis factor-alpha to reduce inflammatory responses.","indications":["Rheumatoid arthritis","Crohn's disease","Psoriatic arthritis","Ankylosing spondylitis"],"catalyst":""},{"name":"Moizerto","genericName":"DIFAMILAST","slug":"difamilast","phase":"marketed","mechanism":"cAMP-specific 3',5'-cyclic phosphodiesterase 4B","indications":["Atopic dermatitis"],"catalyst":""},{"name":"OPC-18","genericName":"OPC-18","slug":"opc-18","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Samtasu for I.V. infusion","genericName":"Samtasu for I.V. infusion","slug":"samtasu-for-i-v-infusion","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TEV-48125","genericName":"TEV-48125","slug":"tev-48125","phase":"phase_3","mechanism":"TEV-48125 is a selective, reversible inhibitor of the sodium-activated potassium channel Nav1.5.","indications":["Atrial fibrillation for stroke prevention"],"catalyst":""},{"name":"13C-uracil","genericName":"13C-uracil","slug":"13c-uracil","phase":"phase_2","mechanism":"13C-uracil is a radiolabeled analog of the pyrimidine nucleoside uracil, used for PET imaging of pyrimidine metabolism.","indications":["Assessment of pyrimidine metabolism in cancer"],"catalyst":""},{"name":"99mTc sulfur colloid","genericName":"99mTc sulfur colloid","slug":"99mtc-sulfur-colloid","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASC-01","genericName":"ASC-01","slug":"asc-01","phase":"phase_3","mechanism":"ASC-01 is a selective androgen receptor modulator (SARM) that activates androgen signaling in a tissue-selective manner.","indications":["Muscle wasting and weakness in older adults","Age-related decline in muscle mass and function"],"catalyst":""},{"name":"ASTX660","genericName":"ASTX660","slug":"astx660","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Aripiprazole (Fixed dose)","genericName":"Aripiprazole (Fixed dose)","slug":"aripiprazole-fixed-dose","phase":"phase_3","mechanism":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that stabilizes dopamine and serotonin neurotransmission in the brain.","indications":["Schizophrenia","Bipolar I disorder (acute manic or mixed episodes)","Major depressive disorder (adjunctive treatment)","Autism spectrum disorder (irritability)"],"catalyst":""},{"name":"Aripiprazole (Titrated dose)","genericName":"Aripiprazole (Titrated dose)","slug":"aripiprazole-titrated-dose","phase":"phase_3","mechanism":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that modulates dopaminergic and serotonergic neurotransmission in the brain.","indications":["Schizophrenia","Bipolar I disorder (acute manic or mixed episodes)","Major depressive disorder (adjunctive treatment)","Autism spectrum disorder (irritability)"],"catalyst":""},{"name":"Aripiprazole oral product","genericName":"Aripiprazole oral product","slug":"aripiprazole-oral-product","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Carteolol long-acting ophthalmic solution","genericName":"Carteolol long-acting ophthalmic solution","slug":"carteolol-long-acting-ophthalmic-solution","phase":"phase_3","mechanism":"Carteolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.","indications":["Glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Hyalein Mini Ophthalmic solution","genericName":"Hyalein Mini Ophthalmic solution","slug":"hyalein-mini-ophthalmic-solution","phase":"phase_3","mechanism":"Hyalein Mini is a hyaluronic acid-based ophthalmic solution that lubricates and protects the ocular surface.","indications":["Dry eye disease","Post-operative ocular surface protection"],"catalyst":""},{"name":"OCV-501","genericName":"OCV-501","slug":"ocv-501","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"OPB-31121 phase2","genericName":"OPB-31121 phase2","slug":"opb-31121-phase2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"OPC-1085EL ophthalmic solution","genericName":"OPC-1085EL ophthalmic solution","slug":"opc-1085el-ophthalmic-solution","phase":"phase_3","mechanism":"OPC-1085EL ophthalmic solution is an anti-inflammatory agent.","indications":["Treatment of dry eye disease"],"catalyst":""},{"name":"OPC-12759","genericName":"OPC-12759","slug":"opc-12759","phase":"phase_3","mechanism":"OPC-12759 is a selective dopamine D2 receptor antagonist.","indications":["Treatment of schizophrenia"],"catalyst":""},{"name":"OPC-12759 Ophthalmic suspension","genericName":"OPC-12759 Ophthalmic suspension","slug":"opc-12759-ophthalmic-suspension","phase":"phase_3","mechanism":"OPC-12759 is an ophthalmic suspension used to treat dry eye syndrome by increasing tear production.","indications":["Treatment of dry eye syndrome"],"catalyst":""},{"name":"OPC-14597 (Aripiprazole)","genericName":"OPC-14597 (Aripiprazole)","slug":"opc-14597-aripiprazole","phase":"phase_3","mechanism":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that stabilizes dopaminergic and serotonergic neurotransmission.","indications":["Schizophrenia","Bipolar I disorder (acute manic or mixed episodes)","Major depressive disorder (adjunctive treatment)","Autism spectrum disorder (irritability)"],"catalyst":""},{"name":"OPC-14597 IMD","genericName":"OPC-14597 IMD","slug":"opc-14597-imd","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"OPC-34712FUM/ Brexpiprazole fumarate","genericName":"OPC-34712FUM/ Brexpiprazole fumarate","slug":"opc-34712fum-brexpiprazole-fumarate","phase":"phase_3","mechanism":"Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors while antagonizing serotonin 5-HT2A receptors.","indications":["Schizophrenia","Major depressive disorder (adjunctive treatment)"],"catalyst":""},{"name":"OPC-41061","genericName":"OPC-41061","slug":"opc-41061","phase":"phase_3","mechanism":"OPC-41061 is a vasopressin V2 receptor antagonist (vaptан) that blocks water reabsorption in the kidney collecting duct, promoting aquaresis and increasing serum sodium levels.","indications":["Hyponatremia associated with heart failure","Hyponatremia associated with cirrhosis","Hyponatremia associated with syndrome of inappropriate antidiuretic hormone secretion (SIADH)"],"catalyst":""},{"name":"OPC-41061 （Tolvaptan)","genericName":"OPC-41061 （Tolvaptan)","slug":"opc-41061-tolvaptan","phase":"phase_3","mechanism":"Tolvaptan is a selective, competitive antagonist of the vasopressin V2 receptor.","indications":["Hyponatremia in hospitalized patients","Autosomal dominant polycystic kidney disease (ADPKD)"],"catalyst":""},{"name":"OPC-415","genericName":"OPC-415","slug":"opc-415","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"OPC-61815 injection","genericName":"OPC-61815 injection","slug":"opc-61815-injection","phase":"phase_3","mechanism":"OPC-61815 is a selective antagonist of the neurokinin-1 (NK1) receptor that reduces substance P signaling in the central nervous system.","indications":["Chemotherapy-induced nausea and vomiting (CINV)"],"catalyst":""},{"name":"OPC-6535","genericName":"OPC-6535","slug":"opc-6535","phase":"phase_3","mechanism":"OPC-6535 is a selective antagonist of the P2X7 receptor, which modulates purinergic signaling involved in inflammatory and immune responses.","indications":["Neuropathic pain"],"catalyst":""},{"name":"Placebo of Aripiprazole","genericName":"Placebo of Aripiprazole","slug":"placebo-of-aripiprazole","phase":"phase_3","mechanism":"This is a placebo control formulation with no active pharmacological mechanism.","indications":["Control arm in phase 3 clinical trials of aripiprazole"],"catalyst":""},{"name":"Placebo of CDP870","genericName":"Placebo of CDP870","slug":"placebo-of-cdp870","phase":"phase_3","mechanism":"This is a placebo control arm and contains no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"Placebo of SPM 962","genericName":"Placebo of SPM 962","slug":"placebo-of-spm-962","phase":"phase_3","mechanism":"Placebos do not have an active pharmacological mechanism; they are used as controls in clinical trials.","indications":[],"catalyst":""},{"name":"Placebo of tolvaptan","genericName":"Placebo of tolvaptan","slug":"placebo-of-tolvaptan","phase":"marketed","mechanism":"A placebo formulation containing no active pharmaceutical ingredient, used as a control comparator in clinical trials of tolvaptan.","indications":[],"catalyst":""},{"name":"SGI-110","genericName":"SGI-110","slug":"sgi-110","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SPM 962","genericName":"SPM 962","slug":"spm-962","phase":"phase_3","mechanism":"SPM 962 is a selective, high-affinity, and orally bioavailable small molecule inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1).","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"Tolvaptan Oral Tablet","genericName":"Tolvaptan Oral Tablet","slug":"tolvaptan-oral-tablet","phase":"phase_3","mechanism":"Tolvaptan is a selective vasopressin V2-receptor antagonist that blocks water reabsorption in the kidney's collecting duct, promoting aquaresis (water excretion) without significant electrolyte loss.","indications":["Hyponatremia associated with syndrome of inappropriate antidiuretic hormone secretion (SIADH)","Hyponatremia in heart failure","Autosomal dominant polycystic kidney disease (ADPKD)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQNEM1b0dMdnFia3JqeUlTZ252UUtzTnFkWTZ3RGhzOFJGLVpEMWFtSlB0YzBjYnFwSTRQb3pkNHVfMG5VR0tMeE40WS1DMUF4dHJFc3p2WHhzQkxrY0VUS0prX0pIaC1XRXNIR21Ccllic1Z6Y01GcE92UFBqLWNCS0hRY3dXRVY0Y01ZeUFFNmlLWXpWY2F0YV9GMl9VSVFtLUlnSERWUQ?oc=5","date":"2026-04-08","type":"pipeline","source":"AD HOC NEWS","summary":"What you need to know for smart investing now - AD HOC NEWS","headline":"What you need to know for smart investing now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNLVpieTFWWEFTWkc0UHdKaF9DY2NQemRqT09MSk1WZFdlU01xdFZNNzhDdkxwVHJfRzlwa3ppRm0xRno3bEFoRXdyRE8yMjMyYk9CeTN3bVFQallneHYtbHNGYXVGMTExRVRtQnU5dlpHUF9UYWtKMHprZE1wci1vWkxxSVNLTVBBVENncXpVMmg1ZTBvcUx6ekV0Yk1oSjJNN0lTUHJEX0Q4M3NVLXFVRQ?oc=5","date":"2026-03-27","type":"deal","source":"PR Newswire","summary":"Otsuka Pharmaceutical to Acquire Transcend Therapeutics - PR Newswire","headline":"Otsuka Pharmaceutical to Acquire Transcend Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxNWjBCNVdLUklJLVRZRGNKSjZWdHdpWWNnSzFpSFVBeWJ0a1VwMGJHcDlwaExYeEhnMVh3VUVQaXVfaEx3VjZnSkJwX3R4a1VHaXFLdGF0N3dOcGNlSGx4S1liQ3hDTTktOWhEVzRydEdnYS16bzRpb3dzZVFIX0o3TGg2T2s2dlVOd0VpaEFNSy04Zm5qWG41Y1huMWdYYkszenFBREN1Wl9EdEU3Y1pfSmJxb2pqNE1IVVRfQnA5UXJkTUZzVkZVNHpERWw?oc=5","date":"2026-02-28","type":"patent","source":"Dentons","summary":"Patent Term Extension in Australia: implications of Otsuka v Sun Pharma and changes in IP Australia practice - Dentons","headline":"Patent Term Extension in Australia: implications of Otsuka v Sun Pharma and changes in IP Australia practice","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPZ2RwRDN3VTcwUlYyUFRSNkZIYjhSblhkMzFZM2p5SDA5NkZSOUpzS1NjOUxWcmEzUlJiYk9KSVQ0aml4VDQwd2hFRm8yT0lhV1dpVlN6U1JsM2cxdkJ5d3dadlhTMlV1bE1kaVVwaEVGMkY3bWllT1hXRVpSeGVYaDhNV3BCZW5GQnM4aEs3Nk5qYjlXbTRJU3A5SU5vME9zM183d3FlbXRRcVhfNC1zbUVxbHlPNXdUZ2dBUEt6SkRHSDNyWTFr?oc=5","date":"2026-02-17","type":"pipeline","source":"NutraIngredients.com","summary":"Otsuka Pharma beefs up POCARI SWEAT production in China - NutraIngredients.com","headline":"Otsuka Pharma beefs up POCARI SWEAT production in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOTHdnOEl1a3AyeXJlSUlERFM4dEdZMU1VU2c2ZHFXNVJuWlB1ZDhKY3ZpcENlbEx3YVdFdnVkV2VxOWNTdGZ6b3VKMXpwQU82R2dqdDRvdkdKYkZzNElzYXJoOVhIc25Rbzg2SzVCNl9SQV9ieVpveDFXY2prSXkzaGhDblhpZWNWaGtteUMxU3RQQ09tSmJRV3Aya0J2TG95ck9NRVlnYXMzY1BXeERWMWNJbk00ZkRxN2VOQ0RRMFBBNjJ2bnhSSy1qQQ?oc=5","date":"2026-02-06","type":"pipeline","source":"BioSpectrum Asia","summary":"Sky Labs inks distribution agreement with Otsuka Pharma for 'CART BP pro' in Japan - BioSpectrum Asia","headline":"Sky Labs inks distribution agreement with Otsuka Pharma for 'CART BP pro' in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxObG0wTkdaeG95N3gzcEQ4QWZGMVRuTGdmQVBERzZTNmxkT055NU9QdTMtemR3aEhuQXEwS1NUZnAxUVdWa084dERhdjAwRkhOZE5haXEySm5SX1ZYNnBfdkZrZmxEVzhkUTI4UXhKNUIwQTRkeVBULXhaeVBSQ0RFUHBBUDRPWlJKQ0tXQ2pGVS1DVGladnBKMjBORlc0NVkzS2c?oc=5","date":"2026-02-05","type":"deal","source":"BioWorld News","summary":"Biodexa licenses Otsuka’s molecular glue OPB-171775 for GIST - BioWorld News","headline":"Biodexa licenses Otsuka’s molecular glue OPB-171775 for GIST","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE9xa0lwSXpLbjRrRlZ4emU4R2J1NVVXYWpuZUpCY05FVk9hYTlrdU5wRElDUFpvcVUwM1dkLWpfYUJ2TXk0bzJDV0FKYkYyWmlhYmJwRUpyZ0pOWGxoVndyeENtVXktVnktV1RwQURrRC1tMXNoTUJYTw?oc=5","date":"2025-12-19","type":"pipeline","source":"otsuka.co.jp","summary":"Otsuka Pharmaceutical Supports Anti-Doping Initiative \"CLEAN SPORT NIPPON SELECT\" - otsuka.co.jp","headline":"Otsuka Pharmaceutical Supports Anti-Doping Initiative \"CLEAN SPORT NIPPON SELECT\"","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wJBVV95cUxPRWNfY2xLRHdNeVg1UXd5aktOU2JXdUpISFR4akdDN0ZiR2NEOWZrQnZkNGg1Zl9MbklMRmw2UngyWGUzVVVweFVQSk84VUQyMVZTY1ZMMFk4d2xLMzJlSXVjbm5MV090YnFQZ1hudnE5eUs3aTVWUmRnN1hORl9tRi1BTkx4YU5COG9CaXZqYnhmcEFwNm1QSGJUdkVJdkctcjZaWlNValkxcTkwdjJqTjFOb1g4NXpMcHZncy0ya29nZjJxX2loUEliV2c2cy1JZGJSTmVMVDNTQlBPSGRiVXUxcF9iX2J6b1R1a1JQOVBzYkZQQThMQm04SlFQQjl3S2RMekFyRENnRTlUMlQzdWZfWXpHbzJfXzVJa04xNERhRHU4eVlxSnl2a2taWGNjYWtJaFlIV2lOdnZTeVhaRmdlWXBGaHNPSDFRczNwc2xsRndBX0lB?oc=5","date":"2025-12-15","type":"regulatory","source":"businesswire.com","summary":"GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe - businesswire.com","headline":"GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxQdmdheFo0eVJIM29RUURMNS1JQnhOSHR0bkFFdG51aXpDVEhYVzRmR1d4THdfZGZhWVY3THN3ZzZILXBsVUEwRzU1ejNGMUJFZ2FRTW1DbjNvOXViT040dWF4WmNpUkJOZzBKRnlPVzA3Y2JWVDVhajZGeVVzQnJtM2VjQkpJNm5fbGVaZDhxOEp5eWtTaFppaGVPaldGcVNqb0N0V0J2Qk5oQV9vVV9KUHlmbjNRY0dkQlNMYzBYbzJXcElBbUN6emhRLVp0SnBXNUJ6WHp1ZElONnVlQlF0cExyS3pCVER2bUpQXzg2a1E3bWRs?oc=5","date":"2025-12-09","type":"patent","source":"Pearce IP","summary":"The End of an Era for Pharma PTEs in AU - Full Court Excludes Formulation Patent Term Extensions in Aripiprazole (ABILIFY) Appeal - Pearce IP","headline":"The End of an Era for Pharma PTEs in AU - Full Court Excludes Formulation Patent Term Extensions in Aripiprazole (ABILIF","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPaFR6dU9CNnFtd0FsY1E2RU0tRGN4dTREeU5pZ0o5NGltc0ZxX2NnbEJ5eFpXdnR5emlHMWtRSXpJYUlnM2tsUVlfTFF5N2hYUmt3SGZISGdsRjhJRzNEN0htaU5FenE5ckNYVzFGQWxQc216b0RVOTNsSUVITTFRbTZZTnpON0E4S0t5UDNDSkNaMmE4akF5eVpIMXQyc3g5TjV6bDNKX3VnRkV5TTVLeFhjYnFKWlBEbGxxVVpQOUhjQlZoYUhpVGNuNVl5UQ?oc=5","date":"2025-12-08","type":"patent","source":"Wolters Kluwer","summary":"Full Federal Court abolishes patent term extensions for pharmaceutical formulations - Wolters Kluwer","headline":"Full Federal Court abolishes patent term extensions for pharmaceutical formulations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxPTHRNNGNqWEZLOV9pb080MnFTbG50LWUxQ05fZTUwUEF2ZGlvRWFBVHF1dDl2ZFB4VGtjMzhFN085MnNGMGhMZmtnOGNSQVVld1R1TTNCdFBSWFZ2clp3ODdQQ0R0YS0zZkEwS1hDQTdSdXhFd0MwMk1CYWl1eTNuZmxXMEd0R0JUZ0FhdnZ0REVFNzN3WER3X1B0ODVxUWw4YmhHdDA1Q2dDN1JvVWlGT1ZjUUhQLXJMc2hzbmhfSlh2TW40ZDJJMEFZOFRDWnYyN1E?oc=5","date":"2025-07-16","type":"regulatory","source":"Reuters","summary":"FDA staff raises efficacy concerns for Otsuka's PTSD combination treatment - Reuters","headline":"FDA staff raises efficacy concerns for Otsuka's PTSD combination treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5qa2xPd3hqUW5sSV82TTZGUXJCbXRVVkMzU3VRMEtLS2JkaWhYQkxmQXAxaDA0ZlZvVzZmbjIzVW9ab01GRHNiREdFdG45R1p1S1Y4?oc=5","date":"2025-07-15","type":"pipeline","source":"FirstWord Pharma","summary":"Otsuka snaps up autoimmune antibody from Swedish biotech - FirstWord Pharma","headline":"Otsuka snaps up autoimmune antibody from Swedish biotech","sentiment":"neutral"}],"patents":[],"drugCount":38,"phaseCounts":{"marketed":3,"phase_2":7,"phase_1":6,"phase_3":22},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}